The European Federation for Medicinal Chemistry (EFMC) is an independent association representing medicinal chemistry societies in Europe. Its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders.

Meetings  July 2018 Next

EFMC Sponsorship rules can be found in the by-laws, point E.

  • Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry “MedChemSicily2018”

    July 17-20, 2018   Palermo, Italy

    The Italian Medicinal Chemistry division, together with the Spanish and Portuguese medicinal chemistry communities, will organize the Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry “MedChemSicily2018”. Palermo, the main city of Sicily rich in history, culture, art, and food, will host the joint meeting from the 17th to 20th of July, 2018. The conference follows similar events, started in 1989 in Granada (1er Congreso Conjunto Hispano-Italiano de Quimica Terapeutica), and then held in 1995 in Ferrara (II Congreso Conjunto Italiano-EspaDol de Quimica Terapeutica), and in 2015 in Barcelona (Spanish-Italian Medicinal Chemistry Congress -SIMCC-2015). As a novelty of the 2018 conference edition, the Portuguese Medicinal Chemistry Society will join Italian and Spanish communities in organizing the event. The following scientists have already accepted to deliver a plenary lecture at the joint meeting: Erick Carreira (ETH Zurich, Switzerland), Ben Davis (University of Oxford, UK), Hervè Galons (University of Paris Descartes, France), and Herbert Waldmann (University of Dortmund, Germany).

    The meeting will coincide with the 25th NMMC & 11th Young Medicinal Chemists Symposium “Nuove Prospettive in Chimica Farmaceutica” (NPCF11). It will be aimed to provide a panel of scientists to interact and discuss the latest ideas, scientific breakthroughs and techniques. The meeting will also offer an exciting chance to debate future changes and to provide topical coverage of key disciplines, and to explore for cooperation and collaborations.

    The scientific programme will include:

    • three days of scientific presentations
    • plenary lectures of eminent international scientists
    • ten parallel oral sessions with keynotes and short communications of distinguished scientists from Italy and abroad (expected attendance of over 400 delegates from Italy and other European countries, both University and Industry)
    • poster sessions
    • an exhibition by companies working in the field

    Plenary Speakers

    • Erick Carreira, ETH Zurich, Switzerland
    • Ben Davis, University of Oxford, UK
    • Hervé Galons, University of Paris Descartes, France
    • Herbert Waldmann, University of Dortmund, Germany
    • Bernhard Wünsch, University of Münster, Germany

    Keynote Speakers

    • Luís G. Arnaut, University of Coimbra, Portugal
    • Pietro Campiglia, University of Salerno, Italy
    • Laura Carzaniga, Chiesi, Parma, Italy
    • Javier Fernández Gadea, Jansen Research & Development, Toledo, Spain
    • Pedro M. P. Góis, University of Lisbon, Portugal
    • Maria Manuel B. Marques, New University of Lisbon, Portugal
    • Marco Mor, University of Parma, Italy
    • Claudia Mugnaini, University of Siena, Italy
    • Rosario Gonzáles-Muñiz, Instituto Quimica Medica-CSIC, Madrid, Spain
    • Antonio Pineda-Lucena, Instituto Investigación Sanitaria La Fe, Valencia, Spain

    Abstract submission deadline: March 31, 2018

    Early Bird registration deadline: April 30, 2018

    Contact person: Prof. Girolamo Cirrincione
    Tel: +39 09123896810

  • 7th RSC / SCI Symposium on GPCRs in Medicinal Chemistry

    September 10-12, 2018   Verona, Italy

    The key role of G protein-coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to announce that Aptuit, Italy will support the seventh meeting in this series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.

    The meeting will consist of:

    • First disclosures of clinical candidates
    • Case studies in GPCR drug discovery and development
    • New structural biology and drug design
    • Allosteric modulation & biased signalling

    Call for Abstracts

    Applications for poster presentations are welcome. Posters will be displayed through the meeting and applicants may indicate whether they wish to be considered for a flash oral presentation when submitting an abstract. Please download a template and send it to the secretariat by 11th July 2018.

    Confirmed Speakers

    • Arthur Christopoulos, Monash University, Australia
    • Brock Shireman, Janssen, United States
    • Chris de Graaf, Vrije Universiteit Amsterdam, Netherlands
    • Chris Tate, MRC Laboratory of Molecular Biology, United Kingdom
    • Cristina Gardelli, AstraZeneca, Sweden
    • Daniel Rosenbaum, University of Texas Southwestern Medical Center, United States
    • Hugo Gutiérrez de Terán, Uppsala University, Sweden
    • Lothar Schwink, Sanofi-Aventis Deutschland, Germany
    • Michael Hanson, GPCR Consortium, United States
    • Miles Congreve, Heptares Therapeutics, United Kingdom
    • Robert Cherney, BMS, United States
    • Xiayang Qiu, Pfizer, United States

    Contact person: Mrs Maggi Churchouse
    Tel: +44 (0)1359 221004

  • 22nd European Symposium on Quantitative Structure-Activity Relationship (22nd EuroQSAR)

    September 16-20, 2018   Thessaloniki, Greece

    The European Quantitative Structure-Activity Relationships (EuroQSAR) Symposia are major scientific events that have been organized in different cities of Europe since 1973. They have the fascinating scope to promote and disseminate advances in rational approaches in drug design and discovery and ensure a worldwide attendance of prominent scientists from both academia and industry.

    The 22nd EuroQSAR 2018 symposium, entitled “Translational and Health Informatics: Implications for Drug Discovery”, will take place September 16-20, 2018 in Thessaloniki, Greece. It is a Turkish-Greek co-organization and an EFMC sponsored event.

    The symposium will focus on:

    • ADME Prediction and Computational Toxicology for Safer and Efficacious Drugs
    • Big Data Analysis, Cloud Resources and Precision Medicine
    • Binding Kinetics in Drug Discovery
    • Biotechnology Targeted Drug Discovery
    • Cheminformatics / Pharmacoinformatics in the Era of Biological Complexity
    • Computational Biology and Quantum Enzymology
    • Computational Methods for Nanotechnology in Drug Discovery
    • Epigenetic Drug Targets
    • Homology Modelling for Drug Discovery
    • Ligand-Based and Structure-Based Approaches to Drug Design
    • Modelling of Natural Drugs
    • Molecular Dynamic Simulations and Related Methods
    • Multi-Targeting Drug Design
    • New avenues in QSAR Methodology and Applications
    • Protein Target Dynamics for Drug Discovery
    • Targeting Protein-Protein Interactions

    The scientific program of the Symposium will include plenary lectures, keynote lectures, oral communications, companies' workshops, poster presentations and a commercial exhibition.

    Organised by : Hellenic Society of Medicinal Chemistry (Greece)

  • Macrocycles 2018 - 3rd RSC BMCS Medicinal Chemistry Symposium on Macrocycles

    October 8-9, 2018   Stevenage, United Kingdom

    The objective of this symposium is to promote scientific interaction between scientists with a shared interest in the field of Macrocycles. This area is responsible for a growing number of therapeutic approaches and development candidates, all of which go ‘beyond the rule-of–five’. As a researcher in this field, come along to hear about the latest advances and also to share in some of the secrets of discovering therapeutic agents which go beyond Lipinski’s rules.

    Confirmed Speakers

    • Frank Fang, Eisai, United States
    • William McCoull, AstraZeneca, United Kingdom
    • Daniel Obrecht, Polyphor, Switzerland
    • Vicky Steadman, Selcia, United Kingdom

    Contact person: Mrs Maggi Churchouse
    Tel: +44 (0)1359 221004

  • 2nd SCI/RSC Symposium on Antimicrobial Drug Discovery

    November 12-13, 2018   London, United Kingdom

    Rising antimicrobial resistance is decreasing the efficacy of existing treatments for infection. With the alarming prospect of a post-antibiotic era, it is vital that we refresh the drug pipeline with new therapies and therapeutics that act through novel modes of action. With pressure from governments and increased public awareness of this growing problem, renewed interest from industry and academia has led to a resurgence in antimicrobial drug discovery, with the exciting prospect of new and innovative technologies and approaches for combating infection.

    Following the first successful event in 2016, this meeting will examine the current state of the art in antimicrobial drug discovery from a medicinal chemist’s perspective. Coinciding with World Antibiotics Awareness week, a two-day programme of speakers from industry and academia will highlight the challenges associated with discovering and developing new antimicrobials, whilst also showcasing emerging strategies that are being developed to tackle infection.

    Early-career researchers wishing to give a short talk are encouraged to submit a one-page abstract by Friday 15 June 2018.

    Deadline for early bird registration is 1st October 2018.

    Contact: Conference Team
    Tel: +44 (0)207 598 1561

25 26 27 28 29 30 01
02 03 04 05 06 07 08
09 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 01 02 03 04 05
All events   |  Future events

Job portal

MsC student or PhD internship, KU Leuven: Cellular and Molecular Medicine, Leuven, Belgium
read more

Medicinal / Synthetic Organic Chemists, Concept Life Sciences: Drug Discovery, Sandwich, Kent, United Kingdom
read more

Job portal page

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on Instagram

ChemBridgeBoehringer IngelheimNovartisProf Dr W. Th. Nauta FoundationPfizerServierRoche
 Prous Institute for Biomedical ResearchUCBJanssen R&DBayerMerck